Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
* Reduction of risk of NSAID-associated gastric ulcers in patients at risk.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. For some patients, 20 mg orally once daily may be sufficient.
* **Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Start with 40 mg orally or intravenously once daily. Doses may be increased as needed. Doses up to 240 mg intravenously have been administered, divided into 40 mg IV infusions every 8 hours.
* **Reduction of NSAID-associated gastric ulcers:** 40 mg orally once daily.
## Pediatric Dosing
Dosing in pediatric patients is highly variable and often based on weight.
* **GERD (erosive esophagitis):**
* Children 5 to 11 years: 20 mg orally once daily for up to 8 weeks.
* Children 5 to 11 years: 40 mg orally once daily for up to 8 weeks.
* Adolescents 12 to 17 years: 40 mg orally once daily for up to 8 weeks.
* **Note:** Safety and efficacy for use beyond 8 weeks have not been established.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness.
* **Serious:** Increased risk of Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia (can be asymptomatic or present with fatigue, muscle spasms, seizures, arrhythmias), vitamin B12 deficiency.
## Key Drug Interactions
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
* **Methotrexate:** Pantoprazole may increase methotrexate levels, leading to toxicity. Consider dose reduction or interruption of pantoprazole.
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Pantoprazole may decrease absorption.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential for increased levels of drugs metabolized by this enzyme.
## Monitoring
* Electrolytes (magnesium, sodium, potassium), especially in patients on long-term therapy or those taking concomitant medications that can lower magnesium.
* Bone mineral density with long-term therapy.
* Signs and symptoms of vitamin B12 deficiency.
* Signs and symptoms of C. difficile infection.
## Clinical Pearls
* PPIs are most effective when taken 30-60 minutes before a meal.
* Long-term use of PPIs (greater than 1 year) is associated with an increased risk of fractures, vitamin B12 deficiency, hypomagnesemia, and possibly an increased risk of certain infections (e.g., pneumonia).
* Discontinuation of PPIs should ideally be tapered to avoid rebound acid hypersecretion.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing may vary based on individual patient factors and local protocols.*
